Detalhe da pesquisa
1.
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(2): 117-135, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38503056
2.
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
Gynecol Oncol
; 177: 165-172, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708581
3.
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
J Natl Compr Canc Netw
; 21(12): 1224-1233, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38081139
4.
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(2): 181-209, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791750
5.
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Br J Cancer
; 126(7): 1027-1036, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34887522
6.
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
Gynecol Oncol
; 161(2): 581-586, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637350
7.
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Gynecol Oncol
; 162(3): 661-666, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34243976
8.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.
J Natl Compr Canc Netw
; 19(8): 888-895, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416706
9.
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
Gynecol Oncol
; 157(3): 578-584, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32265057
10.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Gynecol Oncol
; 159(1): 72-78, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32771276
11.
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.
J Natl Compr Canc Netw
; 18(6): 660-666, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502976
12.
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 17(11): 1374-1391, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31693991
13.
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 17(1): 64-84, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30659131
14.
Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(2): 170-199, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439178
15.
Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(1): 92-120, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28040721
16.
Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.
J Allergy Clin Immunol
; 137(4): 1154-1164.e12, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26725998
17.
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Cancer
; 122(21): 3297-3306, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27421044
18.
Cervical Cancer, Version 2.2015.
J Natl Compr Canc Netw
; 13(4): 395-404; quiz 404, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25870376
19.
Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines.
J Natl Compr Canc Netw
; 13(11): 1321-31, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553763
20.
Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma.
Gynecol Oncol
; 135(1): 54-7, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25088333